Spacing-out of progestin - efficacy, tolerability and compliance of two regimens for hormonal replacement in the late postmenopause

References

• Bachmann G. A. Vulvovaginal complaints. Treatment of the Postmenopausal Woman , R. A. Lobo. Raven Press, New York 1995; 137–42
   Google Scholar
• Blom M. W., Sommers K. The effect of an estradiol transdermal system, alone and in combination with naproxen, on urge incontinence in elderly women: a pilot study. Curr. Ther. Res. 1995; 56: 100–110
   Web of Science ®Google Scholar
• Boerrigter P. J., van de Weijer P. H. M., Baak J. P. A., Fox H., Haspels A. A., Kenemans P. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen. Maturitas 1996; 24: 63–71
   PubMed Web of Science ®Google Scholar
• Cerin A., Heldaas K., Moeller B., for Scandinavian Long-Cycle Study Group. Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy (Letter to the Editor). N. Engl. J. Med. 1996; 334: 668–9
   PubMed Web of Science ®Google Scholar
• Coulomb Y., Piera J. B., Roman F., Pathier D. Urinary incontinence in the menopause: physiopathologic mechanism and treatment. Gaz. Med. 1989; 96: 25–34
   Google Scholar
• David A., Czernobilsky B., Weisglass I. Long-cycle hormonal cycle therapy in postmenopausal women. The Modem Management of the Menopause , G. Berg, M. Hammar. Parthenon, New York 1994; 463–70
   Google Scholar
• Eicher W., Mueck A. O. Treatment of estrogen-deficiency induced sexual disturbances. Gynakol. Geburtshilfliche Rundsch 1996; 36: 83–9
   PubMedGoogle Scholar
• Englund D., Damm S., Hemmingson E., et al. 1993, A study of endometrial effects of a treatment for menopausal symptoms with conjugated estrogens (Premarin) continuously and a progestin (Provera) intermittently every third month. 7th International Congr. Menopause, Stockholm, Sweden, June 20-24, Abstract 3362
   Google Scholar
• Ettinger B., Selby J., Citron J. T., Vangessel A., Ettinger V. M., Hendrickson M. R. Cyclic hormone replacement therapy using quarterly progestin. Obstet. Gynecol. 1994; 83: 693–703
   PubMed Web of Science ®Google Scholar
• Fraser D. I., Parsons A., Whitehead M., Wordsworth J., Stuart G., Pryse Davies J. The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicentre study. Fertil. Steril. 1990; 53: 460–8
   PubMed Web of Science ®Google Scholar
• Haenggi W., Birkhaeuser M. H. A new peroral estrogen/progestin combination for postmenopausal hormonal substitution. Maturitas 1993; 16: 111–22
   PubMed Web of Science ®Google Scholar
• Hahn R. G. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am. J. Obstet. Gynecol. 1989; 161: 1854–58
   PubMed Web of Science ®Google Scholar
• Hirvonen E., Salmi T., Puolakka J., et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen?. Maturitas 1995; 21: 39–44
   PubMed Web of Science ®Google Scholar
• Kemp J. F., Fryer J. A., Baber R. J. An alternative regimen of hormone replacement therapy to improve patient compliance. Aust. N. Z. J. Obstet. Gynaecol. 1989; 29: 66–69
   PubMed Web of Science ®Google Scholar
• Lindgren R., Risberg B., Hammar M., Berg G. Transdermal hormonal replacement therapy with transdermal progestin every second month. Maturitas 1995; 22: 25–30
   PubMed Web of Science ®Google Scholar
• Lindgren R., Risberg B., Hammar M., Berg G., Pryse-Davies J. Endometrial effects of transdermal estradiol/norethisterone acetate. Maturitas 1992; 15: 71–8
   PubMed Web of Science ®Google Scholar
• Lippert T. H., Seeger H., Mueck A. O., Hanke H., Haasis R. Effect of estradiol, progesterone, and progestogens on calcium influx in cell cultures of human vessels. Menopause Q. N. Am. Menopause Soc) 1996; 3: 33–7
   Web of Science ®Google Scholar
• Makinen J., Pitkanen Y., Salmi T., Gronroos M., Paakkari I., Rinne R. Transdermal estrogen for female stress urinary incontinence in postmenopause. Maturitas 1995; 22: 233–8
   PubMed Web of Science ®Google Scholar
• Melchert F., Mueck A. O., Deuringer F. U., Lippert T. H. Transdermal estradiol and chlormadinone acetate orally in urogynecological disorders. Int. J. Gynecol. Obstet. 1994; 46: 180
   Google Scholar
• Meuwissen J. H., Langen H., Nielen M. Growth of endometrium during continuous estrogen substitution monotherapy with Estraderm TTS (0.05/day) in 31 postmenopausal women. Geburtsh. Frauenheilk. 1992; 52: 351–4
   PubMed Web of Science ®Google Scholar
• Miyagawa K., R6sch J., Stanczyk F., Herms-meyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nature Med. 1997; 3: 324–7
   PubMed Web of Science ®Google Scholar
• Mueck A. O., Weber E., Deuringer F. U., Rabe T., Lippert T. H., Runnebaum B. Transdermal hormonal replacement in peri- and postmenopause: bleeding patterns with different progestin regimens. Gynecol. Endocrinol. 1995; 9: 10
   Google Scholar
• Mueck A. O., Deuringer F. U., Melchert F., Weber E., Lippert T. H. Endometrial histology and bleeding patterns during transdermal estradiol with sequential oral chlormadinone acetate. J. Menopause 1994; 1: 26
   Google Scholar
• Mueck A. O., Seeger H., KafJpohl-Butz S., Teichmann A. T., Lippert T. H. Influence of norethisterone acetate and estradiol on the serotonin metabolism of postmenopausal women. Horm. Metab. Res. 1997; 29: 80–3
   PubMed Web of Science ®Google Scholar
• Mueck A. O., Seeger H., Korte K., Lippert T. H. Cardiovascular protection by postmenopausal estrogen replacement therapy: possible mechanisms of the estrogen action. Clin. Exp. Obstet. Gynecol. 1994; 21: 143–9
   PubMedGoogle Scholar
• Mueck A. O., Seeger H., Lippert T. H. Calcium antagonistic effect of natural and synthetic estrogens - investigations on a non-genomic mechanism of direct vascular action. Int. J. Clin. Pharmacol. 1996; 34: 424–6
   Google Scholar
• Mueck A. O., Weber E., Bluemner E. G., Lippert T. H. Transdermal estradiol treatment for climacteric complaints. Multicentre study with 15,194 patients. Munch. Med. Wochenschr. 1994; 136: 85–90
   Google Scholar
• Mueck A. O. Transdermal therapeutic system for physiological estrogen replacement therapy. Therapiewoche 1990; 40: 41–51
   Google Scholar
• Nathorst-Boos J., Wiklund J., Mattsson L. A., Scandin K., von Schoultz B. Is sexual life influenced by transdermal estrogen therapy? A double blind placebo controlled study in postmenopausal women. Acta Obstet. Gynecol. Scand., 72: 656–60
   PubMed Web of Science ®Google Scholar
• Penotti M., Castiglioni E., Nencioni T. Every second month progestogen supplementation during continuous transdermal estrogen replacement therapy. 1993, 7th International Congr. Menopause, Stockholm, Sweden, June 20-24, Abstract 3421
   Google Scholar
• Punnonen R., Kilkku P., Kiukko P. Conservative treatment of urinary incontinence in women with special reference to the use of oestrogens. Maturitas 1981; 3: 309–15
   PubMed Web of Science ®Google Scholar
• Sarrel P. M. How progestins compromise the cardioprotective effects of estrogens. Menopause (J. N. Am. Menopause Soc) 1995; 2: 187–90
   Web of Science ®Google Scholar
• Volterrani M., Rosano G., Coats A., Beale C., Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am. J. Med. 1995; 99: 119–22
   PubMed Web of Science ®Google Scholar
• Whitehead M. I. The effects of oestrogens and progestogens on the postmenopausal endometrium. Maturitas 1978; 1: 87–98
   PubMed Web of Science ®Google Scholar